Real-world
evidence (RWE) is no longer a toy for the privileged few. It’s
insights into disease and patient understanding, existing treatments, value
demonstration and safety are beginning to impact daily operations ranging from
clinical trial design, through to post-launch activities.
 
This new RWE thought-piece will explore how regulators and payers are adapting and facilitating it’s use. It
then examines 4 unique pharma-tech
collaborations, pushing the boundaries of what was previously thought
possible. With expert
insights from:
 
Robert
Califf, Former Commissioner, FDA
·       Peter Speyer,
Global Head of Real World Evidence Solutions, Novartis
·       Brian Otis, CTO, Verily
·       Ajay Royyuru, Fellow and Director of Healthcare and Life Sciences,
IBM
·       Thy Do, Head of Data Generation, Oncology and IBD, Takeda
Follow this link to download your copy: https://goo.gl/wrmFFG